Key Highlights
● Bolt Biotherapeutics climbed strongly on Friday, closing around $4.34, with no announcement from the company.
● Bolt develops immune-based cancer therapies, and no analyst action or filing was tied to the move.
● Moderna rose $28.00 to $225.00, its highest level since 2021, as biotech and cancer-vaccine names rallied.
● No direct link between Bolt's programs and the reported NIH initiative was announced, and Cue Biopharma and PDS also rose.
Bolt Biotherapeutics (NASDAQ:BOLT) climbed strongly on Friday, closing around $4.34 and ranking among the notable gainers on the Nasdaq Composite. The clinical-stage company, which develops immune-based cancer therapies, did not issue any announcement during the session, and no analyst action or filing was tied to the move.
Bolt appeared to be carried by one of Friday's strongest themes: a broad rally in biotechnology, especially among companies working on cancer treatments and vaccines. A major biotech exchange-traded fund rose solidly during the session, and health care was among the best-performing sectors in the S&P 500.
The NIH cancer-vaccine report
The spark for much of that buying was a media report that the National Institutes of Health is planning a public-private Partnership to accelerate cancer Vaccine research. According to the report, the effort is expected to start in December, with an early focus on pancreatic, liver and colorectal cancers as well as some childhood tumors.
Investors rushed into companies seen as potential beneficiaries. Moderna (NASDAQ:MRNA) rose $28.00 to $225.00, its highest level since 2021, on a day that also marked its first session back in the Nasdaq-100. Novavax (NASDAQ:NVAX), BioNTech (NASDAQ:BNTX) and Arcturus Therapeutics (NASDAQ:ARCT) jumped, while larger drugmakers including Pfizer (NYSE:PFE), Merck (NYSE:MRK) and Gilead Sciences (NASDAQ:GILD) also gained.
Smaller oncology names joined in, including ImmunityBio (NASDAQ:IBRX) and Iovance Biotherapeutics (NASDAQ:IOVA). Bolt, whose work focuses on harnessing the immune system against tumors, fits the profile of companies traders gravitated toward, though no direct link between Bolt's programs and the reported NIH initiative was announced.
Small stocks, big swings
Bolt is a small company, and its shares can move dramatically on shifts in sector sentiment. Low-priced, thinly traded stocks can swing sharply in both directions, and moves driven by a theme rather than company-specific data can fade if enthusiasm cools. Several micro-cap biotechs, including Cue Biopharma (NASDAQ:CUE) and PDS Biotechnology (NASDAQ:PDSB), posted large gains on Friday without company news.
Wall Street's broader session
The wider market closed higher. The Nasdaq Composite rose 172.83 points to 27,366.17, the S&P 500 added 46.18 points to 7,811.54, finishing about 7 points shy of its record close, and the Dow Jones Industrial Average climbed 423.31 points to 51,654.95. Software and Cybersecurity stocks led a rebound from Thursday's AI selloff.
Rates remain a headwind for early-stage biotechs, which often depend on raising Capital to fund research. The 10-year Treasury Yield held near a 24-year high, and the Federal Reserve raised rates in September for the first time since 2023. Governor Christopher Waller said Thursday that "For at least the near term, policy will be focused on the Inflation side of our mandate."
Investors also pulled money from US Equity funds during the week, according to market data, the first weekly outflow since mid-September, while bond funds took in a record sum.
More NIH Detail and Any Clinical or Corporate Update From Bolt Could Keep Cancer Biotechs in Focus
More broadly, US stocks trade Monday, October 12, for Columbus Day while the Bond Market is closed. September consumer price data arrives Wednesday, October 14, Johnson & Johnson (NYSE:JNJ) reports on Tuesday alongside the first big banks, and the Federal Reserve meets October 27–28. More detail on the NIH initiative, including which companies or technologies might participate, could keep cancer-focused biotechs in the spotlight ahead of its expected December start. Any clinical or corporate update from Bolt would be the clearest guide for the stock.






Please wait processing your request...